Healthcare Industry News: Biovail
News Release - May 11, 2006
Esprit Pharma Appoints Vice President of Trade
EAST BRUNSWICK, N.J.--(HSMN NewsFeed)--May 11, 2006--Esprit Pharma, Inc. today announced that it has appointed Glenn M. Esgro Vice President of Trade. Mr. Esgro was most recently Sr. Director of Trade for Biovail Pharmaceuticals, Inc. (BVF: NYSE). "We are most pleased to have Glenn join our management team at Esprit Pharma", said Greg Stokes, President and Chief Operating Officer of Esprit. "With his extensive national account sales and sales management experience, Glenn brings the sort of expertise that will greatly help Esprit Pharma achieve its stated goal of pre-eminence in the Specialty Pharma arena", concluded Mr. Stokes.Mr. Chris Dowd, Senior Vice President, Sales at Esprit stated: "Glenn has a proven track record in trade operations and national account management. His experience in trade contracting, customer service and sales management will go a long way in establishing Esprit in the Urology and Women's Health Care fields. All this experience and activities are necessary to Esprit's continued growth", concluded Mr. Dowd.
"I am very excited to be joining a management team with a proven record of success", stated Mr. Esgro. "I believe in Esprit's strategy and goals for growth. I trust that my experience in trade will support Esprit's continued growth", concluded Mr. Esgro.
Mr. Esgro holds a bachelors degree from the University of Richmond. He and his family reside in New Jersey. Mr. Esgro will be based at Esprit's corporate headquarters in East Brunswick, New Jersey.
About Esprit Pharma
Esprit Pharma is a niche oriented, forward thinking pharmaceutical company committed to improving patient outcomes and well-being within the urology and women's health care fields. Led by a highly experienced management team, Esprit focuses on serving the unique needs of physicians by identifying opportunities and selectively acquiring and maximizing the potential of approved and late-stage development medicines and providing support through internal expertise and a dedication to medical education. A privately held company, Esprit has investment support from the leading healthcare venture capital and private equity firms of Domain Associates, LLC (http://www.domainvc.com), New Enterprise Associates (http://www.nea.com) and Apax Partners, Inc. (http://www.apax.com). For additional information visit the Company's Internet site at www.EspritPharma.com.
Source: Esprit Pharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
